Chiesi Limited is an international family-owned company with 80 years of experience focusing on research, development, production and marketing of innovative products for the respiratory, neonatology, rare diseases and other specialised fields. Chiesi has an annual R&D turnover in excess of 20% and the Chiesi pipeline currently includes over 40 projects at various stages of development. Chiesi specialises in respiratory, neonatal and rare diseases with well-known treatments for asthma, COPD, cystic fibrosis and respiratory distress syndrome in premature neonates. The pipeline includes biologic therapies for rare, hereditary glycoprotein diseases that affect multiple systems in the body. Chiesi is committed to improving patient outcomes and quality of life, and recent innovations include the NEXThaler® device, a novel dry powder inhaler with features designed to enhance patient experience for people living with asthma and COPD.